Johnson & Johnson $JNJ Position Increased by Busey Bank

Busey Bank lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 274,245 shares of the company’s stock after buying an additional 6,715 shares during the quarter. Johnson & Johnson makes up 1.4% of Busey Bank’s portfolio, making the stock its 16th biggest position. Busey Bank’s holdings in Johnson & Johnson were worth $50,850,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson in the second quarter valued at approximately $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. boosted its position in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC bought a new position in Johnson & Johnson during the 2nd quarter worth $35,000. Finally, 1248 Management LLC acquired a new stake in Johnson & Johnson in the first quarter worth $48,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on JNJ shares. Johnson Rice set a $190.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Bank of America lifted their price objective on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $210.25.

Johnson & Johnson Stock Down 0.1%

JNJ stock opened at $207.54 on Friday. The firm’s 50-day moving average is $199.67 and its two-hundred day moving average is $181.03. The company has a market capitalization of $500.02 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.